Literature DB >> 22721716

Respiratory response to proton pump inhibitor treatment in children with obstructive sleep apnea syndrome and gastroesophageal reflux disease.

Jolanta Wasilewska1, Janusz Semeniuk, Beata Cudowska, Mark Klukowski, Katarzyna Dębkowska, Maciej Kaczmarski.   

Abstract

OBJECTIVE: Evaluation of the respiratory response to proton pump inhibitors (PPI) in children with obstructive sleep apnea syndrome (OSAS) and gastroesophageal reflux disease (GERD).
METHODS: Of 131 children diagnosed with OSAS (Apnea Hypopnea Index, AHI >1/h), 37 children (6.9 years; 28.24%) with GERD symptoms (>3 times/week) were included. Overnight polysomnography with 24h pH-metry was performed before and after 4-8 weeks of PPI treatment (omeprazole once a day, 1mg/kg).
RESULTS: Of 37 children, 21 were diagnosed with acid GERD where pre- and post-treatment reflux indexes were 14.09±1.47 vs. 7.73±1.36; (p<0.001). The number of obstructive apneas and hypopneas decreased after PPI treatment, resulting in an AHI reduction from 13.08±3.11/h to 8.22±2.52/h; (p<0.01). Respiratory response to PPI ranged from complete resolution of OSA (three children with mild OSA; AHI<5/h; 10.31years; 14.29%) to lack of significant AHI change (six children with severe OSA; AHI>10/h; 3.62 years; 28.57%). Post-treatment AHI was predicted by pre-treatment reflux index (adjusted R(2)=0.487; p<0.001).
CONCLUSIONS: Reduction of obstructive respiratory events following short-term PPI treatment in children with both GERD and OSAS may suggest a causal relationship between apnea and reflux in some children. Questionnaire screening for GERD in children with OSAS may be of benefit.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22721716     DOI: 10.1016/j.sleep.2012.04.016

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  8 in total

Review 1.  Impact of concomitant medications on obstructive sleep apnoea.

Authors:  Ingrid Jullian-Desayes; Bruno Revol; Elisa Chareyre; Philippe Camus; Céline Villier; Jean-Christian Borel; Jean-Louis Pepin; Marie Joyeux-Faure
Journal:  Br J Clin Pharmacol       Date:  2016-11-24       Impact factor: 4.335

2.  Obstructive sleep apnea in young infants with Down syndrome evaluated in a Down syndrome specialty clinic.

Authors:  Alida Goffinski; Maria A Stanley; Nicole Shepherd; Nichole Duvall; Sandra B Jenkinson; Charlene Davis; Marilyn J Bull; Randall J Roper
Journal:  Am J Med Genet A       Date:  2015-01-13       Impact factor: 2.802

3.  Association Between Non-erosive Reflux Disease and High Risk of Obstructive Sleep Apnea in Korean Population.

Authors:  Chan Ran You; Jung Hwan Oh; Minji Seo; Hye Yeon Lee; Hyonsoo Joo; Sung Hoon Jung; Sang Haak Lee; Myung-Gyu Choi
Journal:  J Neurogastroenterol Motil       Date:  2014-04-30       Impact factor: 4.924

Review 4.  Preschool Wheezing and Gastro-Esophageal Reflux: --Causal or Casual Coincidence? Update from Literature.

Authors:  Melissa Borrelli; Giuliana Ponte; Erasmo Miele; Marco Maglione; Carlo Caffarelli; Francesca Santamaria
Journal:  Children (Basel)       Date:  2021-02-28

Review 5.  Obstructive Sleep Apnea in Neonates.

Authors:  Indira Chandrasekar; Mary Anne Tablizo; Manisha Witmans; Jose Maria Cruz; Marcus Cummins; Wendy Estrellado-Cruz
Journal:  Children (Basel)       Date:  2022-03-15

6.  Proton pump inhibition increases rapid eye movement sleep in the rat.

Authors:  Munazah Fazal Qureshi; Sushil K Jha
Journal:  Biomed Res Int       Date:  2014-02-19       Impact factor: 3.411

7.  Sleep patterns and problems among children with 22q11 deletion syndrome.

Authors:  Jill M Arganbright; Meghan Tracy; Susan Starling Hughes; David G Ingram
Journal:  Mol Genet Genomic Med       Date:  2020-03-28       Impact factor: 2.183

Review 8.  Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians.

Authors:  Sonya C Tang Girdwood; Katelyn M Rossow; Sara L Van Driest; Laura B Ramsey
Journal:  Pediatr Res       Date:  2021-04-06       Impact factor: 3.756

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.